cambridge.org/cty

Original Article

Cite this article: Blinder JJ, Huang Y-S, Rossano JW, Costarino AT, and Li Y (2023) Variation in hospital costs and resource utilisation after congenital heart surgery. *Cardiology in the Young* **33**: 420–431. doi: 10.1017/S1047951122001019

Received: 2 June 2021 Revised: 19 January 2022 Accepted: 7 March 2022 First published online: 4 April 2022

Keywords:

Resource utilisation; CHD; cardiac surgery; cardiac intensive care; Hospital costs; PHIS

Author for correspondence:

Joshua J. Blinder, MD, Division of Cardiology, Department of Pediatrics, Lucile Packard Children's Hospital, 750 Welch Road, Suite 321, Palo Alto, CA 94304, USA. Tel: +1 650-724-8075. E-mail: jblinder@stanford.edu

© The Author(s), 2022. Published by Cambridge University Press.



Variation in hospital costs and resource utilisation after congenital heart surgery

Joshua J. Blinder¹, Yuan-Shung Huang², Joseph W. Rossano³, Andrew T Costarino⁴ and Yimei Li^{5,6}

¹Division of Pediatric Cardiology, Lucile Packard Children's Hospital, Stanford University, Palo Alto, CA, USA; ²Department of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA; ³Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; ⁴Division of Cardiac Critical Care, Children's Hospital of Philadelphia, Philadelphia, PA, USA; ⁵Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA and ⁶Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Abstract

Background: Children undergoing cardiac surgery have overall improving survival, though they consume substantial resources. Nationwide inpatient cost estimates and costs at longitudinal follow-up are lacking. Methods: Retrospective cohort study of children <19 years of age admitted to Pediatric Health Information System administrative database with an International Classification of Diseases diagnosis code undergoing cardiac surgery. Patients were grouped into neonates (\leq 30 days of age), infants (31–365 days of age), and children (>1 year) at index procedure. Primary and secondary outcomes included hospital stay and hospital costs at index surgical admission and 1- and 5-year follow-up. Results: Of the 99,670 cohort patients, neonates comprised 27% and had the highest total hospital costs, though daily hospital costs were lower. Mortality declined (5.6% in 2004 versus 2.5% in 2015, p < 0.0001) while inpatient costs rose (5% increase/year, p < 0.0001). Neonates had greater index diagnosis complexity, greater inpatient costs, required the greatest ICU resources, pharmacotherapy, and respiratory therapy. We found no relationship between hospital surgical volume, mortality, and hospital costs. Neonates had higher cumulative hospital costs at 1- and 5-year follow-up compared to infants and children. Conclusions: Inpatient hospital costs rose during the study period, driven primarily by longer stay. Neonates had greater complexity index diagnosis, required greater hospital resources, and have higher hospital costs at 1 and 5 years compared to older children. Surgical volume and in-hospital mortality were not associated with costs. Further analyses comprising merged clinical and administrative data are necessary to identify longer stay and cost drivers after paediatric cardiac surgery.

Children with CHD may require cardiac surgery and resource-intensive perioperative care. Prolonged hospital length of stays following cardiac surgery are due to patient-related and patient-care related factors.¹⁻⁹ While survival has improved over time, many children require life-long care, including multiple hospitalisations, catheter, and surgical interventions into adult-hood.^{10–12} Resource utilisation among this growing survivor population is substantial^{10,13,14} and may be increasing.¹⁵

Existing studies examining CHD resource utilisation are limited to patient subsets (e.g., neonates),^{10,11,16} focused on specific operations,^{11,17-19} or phases of care.²⁰ Cost-influencers were identified, but most were single centre^{10,21} or did not consider inpatient care across age groups.^{15,18,22-26} Except in rare cases, nationwide post-surgical CHD hospital healthcare cost estimates are lacking.^{15,27} To address this knowledge gap, we performed a retrospective cohort study to compare surgical resource utilisation, outcomes as well as readmission and long-term hospital costs associated with CHD surgery.

We hypothesise that children receiving congenital heart surgery consume substantial and increasing healthcare resources and that costs are unevenly distributed across patient age strata and variation exists between hospitals of different surgical volume. We anticipate that most inpatient costs are associated with the first surgery admission (index admission); younger children require more frequent subsequent interventions and have higher long-term hospital costs.

Materials and methods

Data source

The Pediatric Health Information System, managed by the Children's Hospital Association (Lenexa, KS), contains inpatient, emergency department, and observation unit information submitted by over 50 United States not-for-profit, tertiary care paediatric hospitals. Pediatric Health Information System data includes demographics, diagnoses, procedures, discharge disposition, and daily billings for medications, laboratory tests, imaging procedures, clinical services/procedures, supplies, and room and board. Each patient has a unique identifier for longitudinal follow-up. Data quality is assured through a joint effort between the Children's Hospital Association and participating hospitals. This study merited exemption by the Institutional Review Board.

Study cohort and follow-up

The retrospective cohort study identified children <19 years old hospitalised in a Pediatric Health Information System centre between January 2004 and September 2015 and with any cardiac diagnosis (International Classification of Diseases-9 codes: 394.XX-397.XX, 410.XX-417.XX, 420.XX-429.XX, 745.XX-746.XX, 747.0-747.4, V15.87. Only patients receiving cardiac planned surgeries (see Supplemental Table S1) during the index admission were included, and each patient's records from index operation were followed longitudinally for up to 5 years, from index admission to death or the last Pediatric Health Information System hospitalisation discharge.

Covariates

Patients were grouped into three categories based on age at index cardiac surgery: neonates (\leq 30 days at cardiac surgery date), infant (31–365 days), and children (>1 year). Patient characteristics included sex, insurance type (private, public, self, other, or unknown). Genetic syndromes (trisomy 21, trisomy 18, trisomy 13, DiGeorge, Turner, and Williams syndrome) were determined by International Classification of Diseases-9 diagnosis codes at index admission. Chronic complex conditions include congenital and/or genetic anomalies, gastrointestinal, hematologic/immunologic, malignancy, metabolic, neuromuscular, renal, and respiratory defined by Feudtner et al.²⁸ Since all study patients had cardiovascular chronic complex conditions, it was not included as a covariate.

As Pediatric Health Information System only reports discharge diagnoses (not surgical diagnoses), and RACHS-1 score and case ascertainment based on administrative data may be inaccurate, ¹⁷ diagnostic classification from the index surgical admission was assessed based on discharge diagnoses and grouped hierarchically into four diagnostic complexity groups: Simple two ventricle, complex two ventricle, single ventricle, and unclassified.²⁹

Pre-operative length of stays include days from the index surgical admission date to the day before surgery. ICU-level care was determined by pre-operative ICU-level resources and defined *a priori* by specific International Classification of Diseases-9-CM procedure codes or clinical resource utilisation.³⁰ Daily pre-operative resource utilisation was identified from Pediatric Health Information System billing data.

Outcomes

Pediatric Health Information System-adjusted inpatient costs

Pediatric Health Information System provided wage index adjusted charges for each billing item. These charges and the cost-to-charge ratios were multiplied to derive each patient's daily inpatient treatment costs and adjusted to 2017-dollar value with Medical Services component of the Consumer Price Index for overall comparison. Daily adjusted costs were summarised within six billing departments: room and board, pharmacy, laboratory, clinical, supply, and imaging. At follow-up, adjusted overall cost and billing department costs were derived by summing the daily costs reported. All billings were *a priori* grouped into 21 categories (Supplemental Table S2) to describe resource utilisation; the top ten were reported as cost drivers. Cost per inpatient day was calculated by dividing total inpatient cost by inpatient day number during the selected follow-up period.

Mortality, in-hospital length of stays, readmissions, and resource utilisation

Inpatient mortality was evaluated at index surgical admission and at 1- and 5-year follow-up. Pediatric Health Information System discharge status identified inpatient deaths. Index total hospital length of stays were calculated. At each follow-up, total readmission in-hospital days were determined for patients requiring postsurgery discharge hospitalisation.

Post-operative and follow-up ICU resource utilisation and medication use were determined from billing data. Binary indicators for resource exposure on each inpatient day were created and summed to obtain number of exposed days at follow-up.

Statistical analyses

Patient characteristics were summarised using frequencies and percentages for categorical variables and median and interquartile range for continuous variables. Characteristics were compared across age groups using chi-square test for categorical variables and Wilcoxon test for continuous variables. Mortality, resource utilisation, and readmissions during follow-up were compared using the chi-square test; length of stays, resource utilisation days, and cost by the Wilcoxon test.

Time-trend was evaluated using logistic regression (for mortality) and linear regression with gamma distribution (for cost), including year, age group, geographic region, diagnostic complexity, and hospital annual surgical volume. Odds ratio and cost ratio for the current year versus previous year were reported, with 95% confidence intervals.

Hospital volume variation, mortality, and median costs were plotted. Pearson's correlations between hospital mortality and hospital median cost (or hospital annual surgical volume) were estimated to explore the associations between these hospital-level summaries. All analyses were performed in SAS 9.3; two-sided p value of <0.05 was considered significant.

Results

Cohort characteristics

The cohort comprised 99,670 patients from 46 Pediatric Health Information System-contributing institutions during the study period. Neonates represented 27% of the cohort, while 38% were infants and the remaining were older children (Table 1). Females represented 46% (n = 45,656) and 47% (n = 46,371) had public insurance. Sixty-four percent (n = 63,792) were white, 12% were black (n = 12,318), and 15% (n = 14,893) were unclassified. Genetic syndromes were prevalent with trisomy 21 (n = 10,347, 10%) most common. Index diagnostic complexity was highest among neonates with 28% having single ventricle heart disease and 67% having complex two ventricle heart disease (Table 1). Over one-third had chronic complex conditions at index hospitalisation with non-cardiac congenital or genetic anomaly being most common (Table 1).

			Neonate	Infant	Older child	
	All pat	ients	(≤30 days)	(31 day-1 yr)	(>1 year)	
	N = 99,670		N = 27,209	N = 37,720	N = 34,741	
	п	%	%	%	%	P value
Diagnosis group					<0.0001	
Single ventricle	12,314	12.4	27.9	5.9	7.3	
Complex two ventricle	56,049	56.2	67.1	54.7	49.4	
Simple two ventricle	28,560	28.7	4.6	38.1	37.3	
Unclassified	2,747	2.8	0.5	1.4	6.1	
Sex					<0.0001	
Female	45,656	45.8	40.8	48.7	46.6	
Race					<0.0001	
White	63,792	64.0	63.5	63.5	64.9	
Black	12,318	12.4	10.8	13.3	12.6	
Asian	3,953	4.0	3.2	4	4.5	
Other	14,893	14.9	16.9	14.6	13.8	
Unknown	4,714	4.7	5.7	4.6	4.2	
Insurance status					<0.0001	
Public	46,371	46.5	49.9	48.6	41.6	
Private	41,806	41.9	40	39.8	45.8	
Self	1,815	1.8	1.7	1.8	1.9	
Other	8,554	8.6	7.3	8.5	9.7	
Unknown	1,124	1.1	1.1	1.3	1	
Syndromes						
Trisomy 21	10,347	10.4	2.9	21.5	4.2	<0.0001
DiGeorge Syndrome	2,723	2.7	4.5	2.4	1.7	<0.0001
Trisomy 18	145	0.2	0.2	0.2	0.1	<0.0001
Trisomy 13	62	0.1	0.1	0.1	0.0	0.001
Turner	363	0.4	0.8	0.1	0.3	<0.0001
Williams	364	0.4	0.6	0.3	0.2	<0.0001
Chronic Complex Condition						
Number of CCC						
0	63,594	63.8	55.4	57.8	76.9	<0.0001
1	23,526	23.6	24.8	29.0	16.7	
2	8,152	8.2	11.7	9.1	4.4	
3	3,060	3.1	5.3	3.0	1.4	
4+	1,338	1.3	2.8	1.1	0.6	
CCC specific type	_,000	2.0				
Congenital/genetic defect	18,995	19.1	15.3	29.1	11.1	<0.0001
Gastrointestinal	10,102	10.1	17.5	10.5	4.0	<0.0001
Renal	6,515	6.5	14.8	3.9	2.9	<0.0001
Respiratory	6,001	6.0	14.8	6.2	2.3	<0.0001
Neuromuscular	4,483	4.5	6.7	3.7	3.6	<0.0001 (Continue

(Continued)

Table 1. (Continued)

			Neonate	Infant	Older child		
	All pa	atients	(≤30 days)	(31 day-1 yr)	(>1 year)		
	N = 99,670		N = 27,209	N = 37,720	N = 34,741		
	n	%	%	%	%	P value	
Hematologic/immunologic	4,334	4.4	6.4	3.6	3.5	<0.0001	
Metabolic	3,422	3.4	4.2	3.2	3.1	<0.0001	
Malignancy	834	0.8	0.5	0.7	1.3	<0.0001	
Pre-operative ICU-level care							
Respiratory	22,809	22.9	61.7	11.8	4.6	<0.0001	
Cardiac	25,688	25.8	62.1	15.3	8.7	<0.0001	
Renal	445	0.5	0.8	0.2	0.4	<0.0001	
Leukopheresis	82	0.1	0.08	0.1	0.1	0.0414	
Neurological	4	0.0	0.0	0.0	0.0	0.0238	
Pre-operative LOS* (median, IQR)		0, 0-4	5, 3-9	0, 0-1	0, 0-0	<0.0001	
Pre-operative life support							
ЕСМО	851	0.9	1.5	0.5	0.7	<0.0001	
Alprostadil	19,024	19.1	68.5	1.0	0.0r	<0.0001	
IV Inotropes	21,762	21.8	50.6	13.7	8.2	<0.0001	
Dialysis	276	0.3	0.4	0.1	0.4	<0.0001	
Mechanical Ventilator	20,586	20.7	55.9	10.5	4.2	<0.0001	
Inhaled NO	2,561	2.6	6.3	1.6	0.8	<0.0001	

*LOS: In-hospital length of stay, in days

Index surgical admission resource utilisation

Pre-operative hospitalisation (median 5 days, interquartile [3,9]) and ICU-level therapies were more common among neonates (Table 1), including mechanical ventilation (56%) and intravenous inotropic support (51%), (p < 0.001 for all). Post-operative ICU care was common with 91% of patients receiving inotropic support, 78% receiving mechanical ventilation, 14% receiving nitric oxide; neonatal utilisation was highest for all post-operative life support categories while post-operative pharmaceutical utilisation varied across age groups (Table 2, p < 0.001 for all).

Index surgical hospitalisation costs are summarised in Table 3. Overall median patient-level hospital cost was ~\$60,000 in 2017 value. While total neonatal costs were highest (median \$151,587 for neonates, \$51,032 for infants, and \$40,848 for older children, p < 0.0001), neonates had the lowest daily inpatient costs among the three age groups (median \$5650, versus \$6284 for infants, and \$7336 for older children, p < 0.0001), suggesting that longer length of stays were the driver for higher total neonatal hospital costs. Compared across six billing departments, room and board represented the largest cost driver for all age groups (Table 3, p < 0.0001 for all).

In sub-group stratified cost analyses (Table 4a–e), neonates with simple two ventricle diagnosis at index hospitalisation had highest overall hospital costs and lowest daily hospital costs, suggesting that prolonged hospitalisation informed the higher overall hospital costs these children incur (Table 4e) Except for neonates, patients with single ventricle diagnosis had the highest overall hospital costs. After adjusting for hospital length of stay, patients in each age group showed no difference in daily hospitalisation costs across diagnostic groups (Table 4a–b). In contrast to index hospitalisation costs, at 1- and 5-year follow-up, overall hospital costs were highest among the single ventricle diagnosis population (Table 4c–d). Hospital length of stay was longest among infants undergoing simple two ventricle repairs, as compared to more complex two ventricle and single ventricle surgery (Table 4e).

Index surgical hospitalisation costs were further evaluated across 21 resource utilisation sub-categories, the 10 highest of which are reported in Table 3. Room and board accounted for >50% of total and daily hospital costs, whereas imaging, pharmacy supply, and laboratory accounted for <10%. Age-related variation in hospital costs was observed across billing departments (Table 3), with the difference between age groups in the ICU, acute care unit , pharmacotherapy and respiratory therapy categories, and the smallest differences in the anaesthesia category. Non-neonatal infants and older children had higher costs in the "inpatient" (non-ICU or acute care unit) category (Table 3). Greater hospital costs occurred post-operatively for all age groups; neonates had overall higher pre-operative costs (Supplemental Table S3), indicating that ICU care variation occurred across all age groups.

Post-operative outcome and mortality and cost trends

Median post-operative length of stays were 8 days (interquartile 5–16), with neonates having longer post-operative length of stays (Table 2). Index hospitalisation mortality was 4% overall and

Table 2. Post-operative outcomes, index surgical admission

	Age at index surgery						
			Neonate	Infant	Older child		
	All p	atients	(≤30 days)	(31 day-1 yr)	(> 1 year)		
	N = 99,670		N = 27,209	N = 37,720	N = 34,741		
	n	%	%	%	%	P value	
Mortality	3,976	4.0	10.4	1.8	1.4	< 0.000	
Post-operative life support							
ECMO	3,992	4	8.6	2.4	2.1	<0.000	
Alprostadil	7,970	8	28.1	0.6	0.3	<0.000	
Dialysis	3,183	3.2	7.1	1.7	1.3	<0.000	
Inhaled NO	13,595	13.6	26	11.6	6.2	<0.000	
Ventilator							
yes	78,067	78.3	96.2	82.9	59.4	<0.000	
# of days (median, IQR)		2, 1–5	1, 0-4	0	0		
IV Inotropes							
yes	91,064	91.4	96.3	93.9	84.7	<0.000	
# of days (median, IQR)		2, 1-4	5, 2–9	2, 1–4	1, 1–2	<0.000	
Other resource utilisation							
Opioids							
yes	91,261	91.6	88.4	94.3	91.0	<0.000	
number of days (median, IQR)		4, 2–6	2, 0–5	4, 3-6	3, 2–5		
Non-opioid sedatives							
yes	87,083	87.4	83.9	88.7	88.6	<0.000	
number of days (median, IQR)		4, 2–7	6, 2–15	4, 2–7	3, 2–5		
Benzodiazepines							
yes	87,384	87.7	85.6	88.0	89.0	<0.000	
number of days (median, IQR)		2, 1-4	4, 1–9	2, 1–4	1, 1–2		
Diuretics							
yes	93,590	93.9	97.8	98.9	86.5	<0.000	
number of days (median, IQR)		6, 4–13	14, 8–29	6, 4–10	4, 2–6		
Antibiotics							
yes	98,095	98.4	98.6	98.5	98.2	0.000	
number of days (median, IQR)		3, 2–8	7, 3–16	3, 2–6	3, 2–4	<0.000	
Post-operative LOS (median, IQR)		5–16	19, 11–37	7, 5–12	5, 4–8	<0.000	

differed across age groups (10.4% for neonates vs. 1.8% for infant and 1.4% >1 year, p < 0.0001).

Figure 1 showed each hospital's mortality and its relationship to median hospital cost and annual hospital surgical volume. While there was substantial cost (p < 0.001) and mortality (p < 0.001) variation between hospitals, no relationship between hospital mortality and hospital costs (correlation = -0.03, p = 0.831) or surgical volume (correlation = -0.11, p = 0.469) was identified.

Mortality declined during the study period, while overall hospital costs increased (Fig 2a) with a year-over-year adjusted odds ratio 0.90 for mortality (95% confidence intervals 0.89–0.91) and a year-over-year adjusted cost ratio 1.05 for total cost (95% confidence intervals 1.04–1.05). In comparison, daily hospital costs decreased only slightly (Fig 2b): year-over-year adjusted cost ratio 95) 0.993% confidence intervals 0.992–0.994, p < 0.0001), indicating annual 1% decline in daily hospital cost.

One- and five-year outcomes and hospital readmission costs

When stratified by diagnosis complexity group (Fig 3), single ventricle patients had the highest hospital costs at 1- and 5-year followup, while simple two ventricle neonates had higher costs at 1- and 5-year follow-up than neonates with complex two ventricle disease. Among subjects >30 days of age at index operation, those subjects with simple two ventricle operations had the lowest hospital costs at 1- and 5-year follow-up. Table 3. Total costs, index cardiac surgery admission

			Age at index surgery			
			Neonate	Infant	Older Child	
	,	All patients	(<=30 days)	(31 day-1 yr)	(>1 year)	
	N = 99,670		N = 27,209	N = 37,720	N = 34,741	
	Median	IQR	Median	Median	Median	P value
Total Costs						
All departments	\$59,832	\$36,977-\$132,448	\$151,587	\$51,032	\$40,848	<0.000
Clinical	\$5,739	\$2,064-\$16,961	\$16,636	\$4,723	\$3,029	<0.000
Imaging	\$2,810	\$1,590-\$5,636	\$6,224	\$2,458	\$1,970	<0.000
Lab	\$5,725	\$3,182-\$133,399	\$16,270	\$5,196	\$3,340	<0.000
Room and Board	\$30,121	\$18,043-\$65,647	\$78,513	\$26,782	\$19,387	<0.000
Pharmacy	\$4,085	\$2,042-\$10,144	\$10,909	\$3,359	\$2,754	<0.000
Supply	\$7,009	\$3,164-\$14,101	\$11,100	\$5,641	\$6,585	<0.000
Daily (per inpatient day) Costs						
All departments	\$6,403	\$5,092-\$8,117	\$5,650	\$6,284	\$7,336	<0.000
Clinical	\$546	\$258-\$1,081	\$598	\$532	\$497	<0.000
Imaging	\$273	\$175-\$413	\$224	\$269	\$329	<0.000
Lab	\$602	\$407-\$866	\$610	\$620	\$577	<0.000
Room and Board	\$3,207	\$2,597-\$3,882	\$3,054	\$3,234	\$3,341	<0.000
Pharmacy	\$432	\$270-\$679	\$415	\$403	\$487	<0.000
Supply	\$623	\$248-\$1,333	\$387	\$596	\$1,052	<0.000
Top 10 cost categories among 21 categorie	s*					
Operating Room	\$10,470	\$6,903-\$15,872	\$12,969	\$10,024	\$9,574	<0.000
Supplies	\$7,009	\$3,164-\$14,101	\$11,100	\$5,641	\$6,585	<0.000
Lab	\$5,534	\$3,092-\$12,976	\$15,723	\$4,996	\$3,279	<0.000
Pharmacotherapy	\$4,085	\$2,042-\$19,144	\$10,909	\$3,359	\$2,754	<0.000
ICU	\$3,717	\$0-\$14,058	\$23,025	\$3,446	\$1,946	<0.000
ССИ	\$2,880	\$0-\$14,067	\$10,149	\$3,741	\$2,225	<0.000
Radiology	\$2,787	\$1,584-\$5,516	\$6,080	\$2,447	\$1,960	<0.000
Inpatient	\$2,529	\$0-\$7,511	\$1,511	\$2,917	\$2,361	<0.000
Respiratory Therapy	\$1,689	\$650-\$6,025	\$7,122	\$1,581	\$717	<0.000
Anaesthesia	\$725	\$312-\$1,544	\$964	\$697	\$645	<0.000

* Billing-based resource utilisation categories, see Supplemental Table S2 for complete listing

Tables 5 and Supplemental Table S4 summarise mortality, hospital readmission, and hospital costs at 1- and 5-year follow-up, respectively. While most patients (73%) required no hospital readmission at 1-year follow-up, 48% of neonates were readmitted and 54% of the readmitted patients had additional cardiac surgery. Among readmitted, median length of stays were 10 days, with neonates staying twice as long as older children (14 days for neonates, 8 days for infants, and 7 days for older children, p < 0.001). Given the infrequency of hospital readmission, 1-year post-surgery total hospital costs were similar to costs observed during the index operation with neonates (median \$196,362) having the highest hospital costs. Cumulative hospital costs among neonates (Fig 3).

Discussion

In our large, multi-centre cardiac surgery cohort, we identified variations in pre- and post-operative resource utilisation among and across age strata, with neonates contributing the longest index hospitalisation and greatest index hospital costs, 1-year and 5-year hospitalisation costs compared to infants and older children. The findings that neonates had lower daily hospital costs indicated longer length of stays were the primary driver of hospital costs. There were substantial age-related differences in resource utilisation categories; in most categories, neonates required higher costs across these categories. In long-term, post-operative follow-up, only neonates showed significant inpatient resource utilisation. Mortality declined among patients receiving surgery more recently, while Table 4. Median costs by diagnosis complexity and age category

	Neonate	Infant	Older Child	
	(<=30 days)	(31 day-1 yr)	(>1 year)	
a. Total costs during index surgical admission (med	lian)			
Diagnosis Group				
Single Ventricle	\$189,027	\$63,306	\$65,791	
Complex Two Ventricle	\$134,533	\$54,497	\$42,703	
Simple Two Ventricle	\$212,245	\$44,514	\$32,667	
b. Daily costs during index surgical admission (mec	lian)			
Diagnosis Group				
Single Ventricle	\$5,754	\$6,109	\$6,208	
Complex Two Ventricle	\$5,665	\$6,309	\$7,501	
Simple Two Ventricle	\$4,539	\$6,259	\$7,258	
c. Total costs at one-year follow-up after index surg	gical admission (median)			
Diagnosis Group				
Single Ventricle	\$286,197	\$80,852	\$74,020	
Complex Two Ventricle	\$160,842	\$58,496	\$43,985	
Simple Two Ventricle	\$253,474	\$46,653	\$33,287	
d. Total costs at five-year follow-up after index surg	gical admission (median)			
Diagnosis Group				
Single Ventricle	\$335,507	\$130,493	\$81,336	
Complex Two Ventricle	\$172,252	\$62,899	\$45,404	
Simple Two Ventricle	\$271,789	\$48,156	\$33,702	
e. Index admission hospital length of stay after ind	ex operation (days median)			
Diagnosis Group				
Single Ventricle (d)	32	10	11	
Complex Two Ventricle (d)	33	8	5	
Simple Two Ventricle (d)	46	7	4	

surgical-related healthcare costs increased by year, mostly due to longer length of stays.

Interestingly, while daily hospital costs were higher among neonates with single ventricle diagnosis, we observed that those with simple two ventricle diagnosis had greater median overall hospital costs and longest post-surgery hospital stay than those with more complex two ventricle or single ventricle surgery. We postulate that many neonates with simple two ventricle diagnoses (e.g., ventricular septal defect) had important unmeasured (e.g., gestational age, low birth weight) comorbidities which prolonged the hospitalisation contributed to higher post-operative and overall index hospitalisation costs.

While Pasquali identified that children undergoing Society of Thoracic Surgeons' benchmark operations had wide hospital cost variation,¹⁹ we identified no relationship between mortality, surgical volume, and median hospital costs from our long-term cohort follow-up.

Not surprisingly, pre-operative care represented relatively little overall resource burden as few patients were hospitalised pre-operatively. While neonates often required pre-operative ICU care, non-neonatal patients generally did not. In addition, the overall pre-operative length of stays for patients *requiring* pre-operative admission were much shorter compared to the post-operative hospitalisation. While neonates required overall higher pre-operative ICU-level care and had higher pre-operative costs, this was relatively low, suggesting that most were relatively "well" prior to surgical intervention. Our data confirmed findings from previous reports that neonates had more organ system dysfunction compared to non-neonatal subjects, which may increase overall care costs.³¹

We noted decreasing mortality over time coupled with slightly declining daily costs. This trend was observed with recent practice changes after single ventricle palliation with at least some post-surgical convalescent care occurring in the inpatient setting versus at home³². In addition, as overall post-surgery mortality declined, patients are spending longer time in-hospital due to recovery from post-operative morbidities, narcotic weaning, and feeding difficulties. We identified that longer hospital length of stays may not always reflect long ICU-level care.




Figure 1. While we found variation in surgical volume, mortality and median hospital costs, no relationship between surgical volume, mortality, and median hospital costs was identified.

Our observation is that higher neonatal resource utilisation is consistent with previous reports. Neonates require more complex surgery with higher mortality rates.³³ As a result, neonates require more ICU care, including extracorporeal membrane oxygenation, mechanical ventilation, and intravenous therapies compared to older children.^{5,34} Our data are consistent with previous reports identifying that room and board was the principal CHD cost driver.^{12,19,27,35,36} Prolonged hospitalisation would increase utilisation of these expenditures. Neonates required more frequent rehospitalisation translating to 48 and 58% increase in cumulative costs at 1- and 5-year follow-up, compared to relatively insubstantial cost increases observed from infants (0%, 2%) and older children (0%, 0%) (data not reported). As neonates may require readmission following the index operation for surgical or catheter-based reintervention, as well as medical admissions for non-surgical needs, this finding is consistent with clinical practices. Healthcare costs incurred from these subsequent readmissions represent a substantial cost burden for both patient families and society.

Previous reports have suggested a relationship between hospital cardiac surgical volume and post-surgery mortality, that may in part be explainable by local surgical experience and post-operative standardised care practices.^{37–42} While we found substantial variation in hospital costs and mortality, we identified no discernible relationship between hospital volume, mortality and hospital costs. This may at least be partially explained by hospital variations in case-mix which we could not account for in this administrative database analysis.

Our analysis includes several important limitations. First, the Pediatric Health Information System database lacks detailed clinical information, limiting our ability to make important conclusions about the relationship between case-mix and outcomes, though we have used a limited classification scheme to identify anatomic complexity.¹² While we can surmise parts of the clinical state based on resource utilisation (e.g., need for inotropes, mechanical ventilation or renal replacement therapies), we are unable to identify what role hemodynamic residua have in driving variations in hospital costs, resource utilisation and mortality. We lack important patient-level covariates, including prematurity, gestational age, and birth weight, which may influence clinical outcome, but are frequently missing from Pediatric Health Information System administrative data. Important hospitallevel covariates influencing variations in costs, resource utilisation, and outcome may not have been captured. Deaths outside the hospital as well as deaths and hospitalisations at other hospitals could not be captured. Most patients with CHD die in-hospital and were exposed to significant medical technology in the ICU.^{43,44} We lack data regarding resources consumed in the outpatient environment, which may make up a substantial fraction of overall healthcare resources consumed. Recent data found that higher inpatient costs were associated with greater outpatient resource utilisation in a large cohort after tetralogy of Fallot, though the outpatient costs were approximately 30%-40% of inpatient costs.⁴⁵ Due to our large cohort size, result interpretation should focus on the magnitude of estimated effect size (difference) rather than statistical significance (p value). Finally, we




Figure 2 A: While mortality declined, median cumulative hospital costs increased. Adjusted for surgical complexity. B: While mortality declined, median daily hospital costs were relatively constant over time. Adjusted for surgical complexity.




Figure 3. Cumulative median costs at index surgery discharge, 1- and 5-year follow-up.

only have data from centres contributing to the Pediatric Health Information System database; while these tertiary hospitals encompass a substantial fraction of institutions in the United States where cardiac surgery occurs, the findings may not be generalised to other CHD centres.

Conclusions

By establishing one of the largest paediatric CHD surgical cohorts and following each patient's hospital care for 5 years, we observed two important trends: an annual mortality rate reduction over the study period with a concomitant annual increase in CHD surgery costs. We identified several drivers associated with variations in hospital costs, including the role longer hospital length of stays may play in the observed hospital total cost increases. Neonates utilise the largest portion of inpatient hospital resources and consume substantial additional hospital resources after index hospital discharge due to subsequent hospital readmission. While there was hospital mortality and cost variation between institutions, we identified no discernable pattern among surgical volume, mortality, and hospital costs. Further analysis with more detailed clinical data merged with administrative data is necessary to understand factors driving variations in outcome, resource utilisation, and hospital costs among children undergoing cardiac surgery.

Table 5. Hospital readmissions and costs, one-year post-index surgical admission

			Age at index surgery			
			Neonate	Infant	Older Child	
	All patients		(<=30 days)	(31 day-1 yr)	(>1-year)	
		N = 99,670	N = 27,209	N = 37,720	N = 34,741	
	п	%	%			P value
No. of readmissions						
0	72,861	73.1	52.1	76.9	85.5	<0.0001
1	14,399	14.4	21.8	13.4	9.8	
2	6,171	6.2	12.4	5	2.7	
3+	6,239	6.3	13.7	4.7	2	
No. of readmissions requiring surgery						
0	85,321	85.6	63.8	91.4	96.4	<0.0001
1	11,392	11.4	27.9	7.1	3.2	
2	2,365	2.4	6.7	1.1	0.3	
3+	592	0.6	1.6	0.4	0.1	
Mortality	5,019	5.0	12.7	2.6	1.7	<0.0001
		Median	IQR	Median, IQR	Median, IQR	Median, IQF
Length of follow-up, in days (max 365 days)	11	5–69	79, 21–201	9, 6–35	5, 4–11	<0.0001
Total in-hospital LOS	10	5–28	34, 19–68	9, 6–19	5, 4–9	<0.0001
Total readmission LOS, among readmitted	10	5–23	14, 7–30	8, 4–19	7, 4–14	<0.0001
Total Costs within 1-year						
All departments	65,825	\$38,169-\$166,386	\$196,362	\$54,670	\$42,257	<0.0001
Clinical	6,626	\$2,244-\$21,168	\$22,434	\$5,202	\$3,192	<0.0001
Imaging	3,119	\$1,676-\$7,042	\$8,199	\$2,634	\$2,089	<0.0001
Lab	6,158	\$3,285-\$16,063	\$20,093	\$5,473	\$3,424	<0.0001
Room and Board	33,233	\$18,711-\$82,267	\$100,525	\$28,893	\$20,118	<0.0001
Pharmacy	4,492	\$2,142-\$12,506	\$14,003	\$3,626	\$2,858	<0.0001
Supply	7,754	\$3,413-\$16,636	\$14,595	\$6,044	\$6,815	<0.0001

Supplementary material. To view supplementary material for this article, please visit https://doi.org/10.1017/S1047951122001019

Financial support. This research received no specific grant from any funding agency, commercial or not-for-profit sectors.

Conflicts of interest. Dr. Rossano reports consultant relationships with Amgen, Bayer, CSL Behring, Novartis. The remaining authors report no conflicts.

Ethical standards. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national guidelines with the use of protected health information and with the Helsinki Declaration of 1975, as revised in 2008, and have been approved by the Children's Hospital of Philadelphia Institutional Review Board.

References

 Alsoufi B, Gillespie S, Mahle WT et al. The effect of noncardiac and genetic anomalies on outcomes following neonatal congenital heart surgery. Semin Thorac Cardiovasc Surg 2016;28:105–114.

- Alten JA, Klugman D, Raymond TT et al. Epidemiology and outcomes of cardiac arrest in pediatric cardiac ICUs. Pediatr Crit Care Med 2017;18:935–943.
- Alten JA, Rahman AK, Zaccagni HJ et al. The epidemiology of healthcareassociated infections in pediatric cardiac intensive care unitss. Pediatr Infect Dis J 2018;37:768–778.
- 4. Bell JL, Saenz L, Domnina Y et al. Acute neurologic injury in children admitted to the cardiac Intensive Care Unit. Ann Thorac Surg 2019;Jan 22:epub ahead of print.
- Blinder JJ, Thiagarajan R, Williams K, Nathan M, Mayer J, Kulik TJ. Duration of mechanical ventilation and perioperative care quality after neonatal cardiac operations. Ann Thorac Surg 2017;103:1956–1962.
- Desai J, Aggarwal S, Lipshultz S et al. Surgical interventions in infants born preterm with congenital heart defects: an analysis of the Kid's inpatient database. J Pediatr 2017;191:103–109.
- Howard TS, Kalish BT, Wigmore D et al. Association of extracorporeal membrane oxygenation support adequacy and residual lesions with outcomes in neonates supported after cardiac surgery. Pediatr Crit Care Med 2016;17:1045–1054.
- Koth AM, Algaze CA, Sakarovitch C et al. Younger age remains a risk factor for prolonged length of stay after bidirectional cavopulmonary anastomosis. Cardiol Young 2019;29:369–374.

- Nathan M, Gauvreau K, Liu H et al. Outcomes differ in patients who undergo immediate intraoperative revision versus patients with delayed postoperative revision of residual lesions in congenital heart operations. J Thorac Cardiovasc Surg 2014;148:2540–6 e1–5.
- Downing TE, Allen KY, Goldberg DJ et al. Surgical and catheter-based reinterventions are common in long-term survivors of the Fontan operation. Circ Cardiovasc Interv 2017;10:1–9.
- Nelson JS, Pasquali SK, Pratt CN et al. Long-term survival and reintervention after the Ross procedure across the pediatric age spectrum. Ann Thorac Surg 2015;99:2086–2094.
- Burstein DS, Shamszad Pl, Dai D et al. Significant mortality, morbdity and resource utilization associated with advanced heart failure in congenital heart disease in children and young adults. Am Heart J 2019;Mar:209–219.
- Zielonka B, Snarr BS, Liu MY et al. Resource utilization for prenatally diagnosed single-ventricle cardiac defects: a Philadelphia fetus-to-Fontan cohort study. J Am Heart Assoc 2019;8:1–10.
- Jacobs JP, O'Brien SM, Pasquali SK et al. The importance of patient-specific preoperative factors: an analysis of the society of thoracic surgeons congenital heart surgery database. Ann Thorac Surg 2014;98:1653–8; discussion 1658–9.
- Mackie AS, Tran DT, Marelli AJ, Kaul P. Cost of congenital heart disease hospitalizations in Canada: a population-based study. Canadian Journal of Cardiology 2017;33:792–798.
- Smith AH, Gay JC, Patel NR. Trends in resource utilization associated with the inpatient treatment of neonatal congenital heart disease. Congenit Heart Dis 2013;9:96–105.
- Pasquali SK, Peterson ED, Jacobs JP et al. Differential case ascertainment in clinical registry versus administrative data and impact on outcomes assessment for pediatric cardiac operations. Ann Thorac Surg 2013;2013:1.
- Pasquali SK, Sun JL, Almada PD et al. Center variation in hospital costs for patients undergoing congenital heart surgery. Circ Cardiovasc Qual Outcomes 2011;4:306–312.
- Pasquali SK, Jacobs ML, He X et al. Variation of congenital heart surgery costs across hospitals. Pediatrics 2014;133:553–560.
- Edelson JB, Rossano JW, Griffis H et al. Emergency department visits by children with congenital heart disease. J Am Coll Cardiol 2018;72: 1817–1825.
- Czosek RJ, Anderson JB, Heaton PC, Cassedy A, Schnell B, Cnota JF. Staged palliation of hypoplastic left heart syndrome: trends in mortality, cost, and length of stay using a national database from 2000 through 2009. Am J Cardiol 2013;111:1792–1799.
- Pinto NM, Waitzman N, Nelson R, Minich L, Krikov S, Botto LD. Early childhood inpatient costs of critical congenital heart disease. J Pediatr 2018;203.
- 23. Simeone RM, Oster ME, Hobbs CA, Robbins JM, Collins RT, Honein MA. Popoulation-based study of hospital costs for hospitalizations of infants, children and adults with a congenital heart defect, Arkansas 2006–2011. Birth Defects Res Part A Clin Mol Teratol 2015;103:814–820.
- Ungerleider RM, Bengur AR, Kessenich AL et al. Risk factors for higher cost in congenital heart operations. Ann Thorac Surg 1997;64:44–49.
- Connor JA, Gavreau K, Jenkins KJ. Factors associated with increased resource utilization for congenital heart disease. Pediatrics 2005;116: 689–695.
- 26. Jantzen DW, He X, Jacobs JP et al. The impact of differential case ascertainment in clinical registry versus administrative data on assessment of resource utilization in pediatric heart surgery. World J Pediatr Congenit Heart Surg 2014;5:398–405.
- Huang L, Schilling C, Dalziel KM et al. Hospital inpatient costs for single ventricle patients surviving the Fontan procedure. Am Heart J 2017; 120:467–472.

- Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr 2014;14:199.
- Burstein DS, Shamszad P, Dai D, et al. Significant mortality, morbidity and resource utilization associated with advanced heart failure in congenital heart disease in children and adults. Am Heart J 2018;209:9–19.
- Maude SL, Fitzgerald JC, Fisher BT, et al. Outcome of pediatric acute myeloid leukemia subjects receiving intensive care in the United States. Pediatr Crit Care Med 2014;15:112–120.
- Brown KL,Ridout D, Pagel C et al. Incidence and risk factors for important early morbidities associatedw ith pediatric cardiac surgery in a UK population. J Thorac Cardiovasc Surg 2019;158:1185–1196.
- McHugh KE, Pasquali SK, Hall MA, Schurer MA. Cost variation across centers for the Norwood operation. Ann Thorac Surg 2018;105: 851–856.
- Berger JT, Holubkov R, Reeder R et al. Morbidity and mortality prediction in pediatric heart surgery: physioloigc profiles and surgical complexity. J Thorac Cardiovasc Surg 2017;154:620–628.
- 34. Brunetti MA, Gaynor JW, Retzloff L et al. Characteristics, risk factors, and outcomes of extracorporeal membrane oxygenation use in pediatric cardiac ICUs: a report from the pediatic cardiac critical care consortium registry. Pediatr Crit Care Med 2018;19:544–552.
- 35. Burstein DS, Li Y, Getz KD et al. Mortality, resource utilization and inpatient costs vary among pediatric heart transplant indiciations: a merged data set analysis from the united network for organ sharing and pediatric health information systems databases. J Card Fail 2019; 2019:1.
- Huang L, Dalziel KM, Schilling C et al. Hospital costs and cost implications of co-morbid conditions for patients with single ventricle in the period through to Fontan completion. Int J Cardiol 2017;240:178–182.
- Welke KF, Pasquali SK, Lin P et al. Regionalization of congenital heart surgery in the United States. Semin Thorac Cardiovasc Surg 2019; epub ahead of print.
- Welke KF, Diggs BS, Karamlou T, Ungerleider RM. The relationship between hospital surgical case volumes and mortality rates in pediatric cardiac surgery, 1988–2005. Ann Thorac Surg 2008;86:889–896.
- Welke KF, O'Brien SM, Peterson ED, Ungerleider RM, Jacobs ML, Jacobs JP. The complex relationship between pediatric cardiac surgical vase volumes and mortality rates in a national clinical database. J Thorac Cardiovasc Surg 2009;137:1133–1140.
- Pasquali SK, Li JS, Burstein DS et al. Association of center volume with mortality and complications in pediatric heart surgery. Pediatrics 2012;129:e370–3376.
- Kalfa D, Chai P, Bacha E. Surgical volume-to-outcome relationship and monitoring of technical performance in pediatric cardiac surgery. Pediatr Cardiol 2014;35:899–905.
- Hirsch JC, Gurney JG, Donahue JE, Gebremariam A, Bove EL, Ohye RG. Hospital mortality for Norwood and arterial switch operations as a function of institutional volume. Pediatr Cardiol 2008;29:713–717.
- Morell E, Wolfe J, Schurer M, Thiagarajan R, et al. Patterns of care at end of life in children with advanced heart disease. Arch Pediatr Adolesc Med 2012;166:745–748.
- Hollander SA, Dykes JC, Chen S, Barkoff L, et al. The end-of-life experience of pediatric heart transplant recipients. J Pain Symptom Manage 2017;53:927–931.
- 45. O'Byrne ML, Decost, G, Katcoff H, Savla JJ, et al. Resource utilization in the first 2 years following operative correction for tetralogy of Fallot: study using data from the Optum's de-identified clinformatics data mart insurance claims database. J Am Heart Assoc 2020; 9: e016581.